Search
Cardiolipin Biosynthesis CL(16:0/20:0/20:0/20:0)
smpdb.ca/view/SMP0206912MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Pegargiminase
go.drugbank.com/drugs/DB06592InvestigationalPegargiminase is an anticancer agent.
Categories: Compounds used in a research, industrial, or household settingSynonyms: ADI-PEG 20Plasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia). … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with
Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
go.drugbank.com/drugs/DB15728ExperimentalOne of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing. … The condition medium (CM) derived from these MSCs has also been implicated in therapeutic properties.
Synonyms: Allogeneic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media, Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned MediaXAV-19
go.drugbank.com/drugs/DB15895InvestigationalAs of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384). … Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558].
Tivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalRenal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
AZD-9164
go.drugbank.com/drugs/DB12115InvestigationalAZD9164 has been used in trials studying the basic science and treatment of Chronic Obstructive Pulmonary Disease.
Categories: Receptor, Muscarinic M3, antagonists & inhibitorsNitenpyram
go.drugbank.com/drugs/DB11438ExperimentalVet approvedNitenpyram is an insecticide used in agriculture and veterinary medicine to kill external parasites of pets. … It is a neonicotinoid, a neurotoxin that blocks neural messages and binds particularly tightly in the central nervous system of insects, causing rapid death.
Categories: Compounds used in a research, industrial, or household settingSynonyms: (E)-nitenpyram, (1E)-N-((6-chloro-3-pyridinyl)methyl)-N-ethyl-N'-methyl-2-nitro-1,1-ethenediamineCythioate
go.drugbank.com/drugs/DB11392ExperimentalVet approvedCythioate is a member of the organothiophosphate compounds that is used as an insecticide and anthelmintic. It is mainly used in veterinary as a treatment for fleas.
Categories: Compounds used in a research, industrial, or household setting